NRXP
NRX Pharmaceuticals, Inc.
$4.16
+0.22 (+5.45%)
At close · Jul 7
Market Cap
$151.80M
Shares
36,228,992
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.16
Open$3.95
Day$3.87–4.22
52W$1.62–5.06
Avg vol 30d1.4M
Short int5.7M · 15.8% float · 3.3d
Short vol32%
Last earningsDec 31, 2025
DataJan 2020–Jul 2026
Filing10-Q · May 15
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.1 · calm
Equity put/call 0.69
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+53%
above
Price vs 50-day avg
+15%
above
RSI (14)
59
neutral
MACD trend
Negative
52-week position
74%
mid-range
Momentum
relative strength
1-month return
0%
trailing
6-month return
+87%
trailing
YTD return
+54%
this year
Relative strength
+80%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow
Accumulating
+13% holders QoQ · +11 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
15.76% of float · ▲ +14.8% MoM · 3.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
34 holders — near 2-yr high, broad support
Squeeze score
75
high risk · 0–100
Fundamentals
EPS growth
+70%
Y/Y
Balance sheet
$1.4M
net debt
Quant / Vol
risk profile
Volatility
86%
annualized · 1-yr
Max drawdown
−54%
past year
ATR
7.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+53%
Bullish
Price vs 50-day avg
+15%
Bullish
RSI (14)
59
Neutral
MACD trend
Negative
Bearish
52-week position
74%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow
Accumulating
+13% holders QoQ · +11 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
15.76% of float · ▲ +14.8% MoM · 3.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
34 holders — near 2-yr high, broad support
Price context
position in its 52-week range
52-wk low $2
Now $4 · 74%
52-wk high $5
vs 200-day avg +53%
vs 50-day avg +15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NRXP
this stock
NRX Pharmaceuticals, Inc.
|
$151.80M | +53.5% | — | — | 15.8% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.49B | +9.4% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NRXP | +4.0% | +0.5% | +87.4% | +1.7% | +53.5% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | +3.1% | -0.9% | +79.8% | +1.6% | +43.9% |